Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.
Journal
Journal of Clinical Oncology
Series/Report No.
Journal of Clinical Oncology
Journal Volume
42
Journal Issue
16_suppl
Start Page
2582
End Page
2582
Date Issued
2024-01-01
Author(s)
Wang J.S.
Sommerhalder, David
Sharma, Manish
Edenfield, William Jeffery
Sehgal, Kartik
Oh, Do-Youn
Jiang, Yixing
Michalski, Joel
Lee, Jeeyun
Hammers, Hans J.
Bai, Li-Yuan
Dampier, Brenda A. P.
Zhou, Kefei
Blum, Lisa K.
Lancaster, Joanne Sloan
Abhyankar, Dhiraj J.
Lieu, Hsiao D.
Hanes, Vladimir
Naing, Aung
Type
text::journal::journal article